| Integrated genomic characterization of papillary thyroid carcinoma N Agrawal, R Akbani, BA Aksoy, A Ally, H Arachchi, SL Asa, JT Auman, ... Cell 159 (3), 676-690, 2014 | 2689 | 2014 |
| Network-based stratification of tumor mutations M Hofree, JP Shen, H Carter, A Gross, T Ideker Nature methods 10 (11), 1108-1115, 2013 | 895 | 2013 |
| Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions JP Shen, D Zhao, R Sasik, J Luebeck, A Birmingham, ... Nature methods 14 (6), 573-576, 2017 | 387 | 2017 |
| Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease JE Bradner, R Mak, SK Tanguturi, R Mazitschek, SJ Haggarty, K Ross, ... Proceedings of the National Academy of Sciences 107 (28), 12617-12622, 2010 | 232 | 2010 |
| Novel third-generation EGFR tyrosine kinase inhibitors and strategies to overcome therapeutic resistance in lung cancer A Murtuza, A Bulbul, JP Shen, P Keshavarzian, BD Woodward, ... Cancer Research 79 (4), 689-698, 2019 | 188 | 2019 |
| Genetic interaction mapping in mammalian cells using CRISPR interference D Du, A Roguev, DE Gordon, M Chen, SH Chen, M Shales, JP Shen, ... Nature methods 14 (6), 577-580, 2017 | 175 | 2017 |
| A network of conserved synthetic lethal interactions for exploration of precision cancer therapy R Srivas, JP Shen, CC Yang, SM Sun, J Li, AM Gross, J Jensen, K Licon, ... Molecular cell 63 (3), 514-525, 2016 | 168 | 2016 |
| A robust small-molecule microarray platform for screening cell lysates JE Bradner, OM McPherson, R Mazitschek, D Barnes-Seeman, JP Shen, ... Chemistry & biology 13 (5), 493-504, 2006 | 162 | 2006 |
| A global transcriptional network connecting noncoding mutations to changes in tumor gene expression W Zhang, A Bojorquez-Gomez, DO Velez, G Xu, KS Sanchez, JP Shen, ... Nature genetics 50 (4), 613-620, 2018 | 149 | 2018 |
| Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss AM Gross, RK Orosco, JP Shen, AM Egloff, H Carter, M Hofree, ... Nature genetics 46 (9), 939-943, 2014 | 146 | 2014 |
| Few-shot learning creates predictive models of drug response that translate from high-throughput screens to individual patients J Ma, SH Fong, Y Luo, CJ Bakkenist, JP Shen, S Mourragui, LFA Wessels, ... Nature Cancer 2 (2), 233-244, 2021 | 139 | 2021 |
| Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). X Gao, HA Burris III, J Vuky, R Dreicer, AO Sartor, CN Sternberg, ... Journal of Clinical Oncology 40 (6_suppl), 17-17, 2022 | 131 | 2022 |
| Patient-derived micro-organospheres enable clinical precision oncology S Ding, C Hsu, Z Wang, NR Natesh, R Millen, M Negrete, N Giroux, ... Cell Stem Cell 29 (6), 905-917. e6, 2022 | 92 | 2022 |
| Phase I/II trial of encorafenib, cetuximab, and nivolumab in patients with microsatellite stable, BRAFV600E metastatic colorectal cancer. VK Morris, CM Parseghian, M Escano, B Johnson, KPS Raghav, A Dasari, ... Journal of Clinical Oncology 40 (4_suppl), 12-12, 2022 | 71 | 2022 |
| Genomic landscape of appendiceal neoplasms CSP Ang, JP Shen, CJ Hardy-Abeloos, JK Huang, JS Ross, VA Miller, ... JCO Precision Oncology 2, 1-18, 2018 | 71 | 2018 |
| Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers B Garmezy, J Gheeya, HY Lin, Y Huang, T Kim, X Jiang, KZ Thein, ... JCO Precision Oncology 6, e2100267, 2022 | 70 | 2022 |
| Relative abundance of SARS-CoV-2 entry genes in the enterocytes of the lower gastrointestinal tract JJ Lee, S Kopetz, E Vilar, JP Shen, K Chen, A Maitra Genes 11 (6), 645, 2020 | 70 | 2020 |
| Comprehensive Clinical and Molecular Characterization of KRASG12C-Mutant Colorectal Cancer JT Henry, O Coker, S Chowdhury, JP Shen, VK Morris, A Dasari, ... JCO Precision Oncology 5, 613-621, 2021 | 69 | 2021 |
| Survival improvement for patients with metastatic colorectal cancer over twenty years FA Zeineddine, MA Zeineddine, A Yousef, Y Gu, S Chowdhury, A Dasari, ... NPJ Precision Oncology 7 (1), 16, 2023 | 66 | 2023 |
| Disruption of NSD1 in Head and Neck Cancer Promotes Favorable Chemotherapeutic Responses Linked to Hypomethylation N Bui, JK Huang, A Bojorquez-Gomez, K Licon, KS Sanchez, SN Tang, ... Molecular cancer therapeutics 17 (7), 1585-1594, 2018 | 56 | 2018 |
Trey IdekerUniversity of California San DiegoEmail verificata su ucsd.edu